Zobrazeno 1 - 5
of 5
pro vyhledávání: '"D Tardiff"'
Autor:
M Ghannad, M Dennehy, C la Porte, I Seguin, D Tardiff, R Mallick, E Sabri, G Zhang, S Kanji, D W Cameron
Publikováno v:
PLoS ONE, Vol 14, Iss 10, p e0223969 (2019)
Effects of steady-state rifabutin on the pharmacokinetics of steady-state maraviroc were investigated in fourteen healthy adult female and male volunteers. Maraviroc 300 mg twice daily (BID) was given orally with food for fifteen days. On day six, ri
Externí odkaz:
https://doaj.org/article/007c10680b4842e7946c9380b2a5850c
Autor:
Salmaan Kanji, Isabelle Seguin, C. la Porte, M. Dennehy, Guijin Zhang, M. Ghannad, Elham Sabri, D. W. Cameron, Ranjeeta Mallick, D. Tardiff
Publikováno v:
PLoS ONE, Vol 14, Iss 10, p e0223969 (2019)
PLoS ONE
PLoS ONE
Effects of steady-state rifabutin on the pharmacokinetics of steady-state maraviroc were investigated in fourteen healthy adult female and male volunteers. Maraviroc 300 mg twice daily (BID) was given orally with food for fifteen days. On day six, ri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddea84e05cb923e8e5a567160e772789
https://doaj.org/article/007c10680b4842e7946c9380b2a5850c
https://doaj.org/article/007c10680b4842e7946c9380b2a5850c
Autor:
Thomas H. Barton, D. Tardiff
Publikováno v:
Conference Record of the IEEE Industry Applications Society Annual Meeting.
Various resonant circuits are reviewed and compared in order to unify the different design methods that are available for low-loss snubbers. Two passive resonant snubbers are described in detail, with some design guidelines for selecting all the snub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95bb2d7e24f3dbd834db4ff26c0f7610
https://doi.org/10.1109/ias.1989.96791
https://doi.org/10.1109/ias.1989.96791
Autor:
Ghannad M; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Dennehy M; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.; Clinical Investigation Unit, The Ottawa Hospital, Ottawa, Ontario, Canada., la Porte C; Clinical Investigation Unit, The Ottawa Hospital, Ottawa, Ontario, Canada., Seguin I; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Tardiff D; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Mallick R; Ottawa Methods Centre, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Sabri E; Ottawa Methods Centre, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Zhang G; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Kanji S; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.; The Ottawa Hospital, Department of Pharmacy, Ottawa, Ontario, Canada.; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Cameron DW; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.; Division of Infectious Diseases, Department of Medicine, University of Ottawa at The Ottawa Hospital, Ottawa, Ontario, Canada.
Publikováno v:
PloS one [PLoS One] 2019 Oct 24; Vol. 14 (10), pp. e0223969. Date of Electronic Publication: 2019 Oct 24 (Print Publication: 2019).
Autor:
la Porte C; Ottawa Hospital Research Institute, Ottawa, Ontario K1H 8L6, Canada. claporte@ohri.ca, Voduc N, Zhang G, Seguin I, Tardiff D, Singhal N, Cameron DW
Publikováno v:
Clinical pharmacokinetics [Clin Pharmacokinet] 2010 Jul; Vol. 49 (7), pp. 449-54.